Biomerica profit margin BMRA
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- n/m
- not a meaningful number
- Peer median
- 7.6%
Biomerica's net margin works out at −115% over the last twelve months, but it is not a meaningful number: a margin outside minus 100% to 100% is moved by items that are not sales.
Profit margin over time
GrossOperatingNet
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2026 | −84.8% | n/a | 8.1% |
| FY2025 | −93.6% | −96.7% | 9.4% |
| FY2024 | n/a | n/a | 11.2% |
| FY2023 | n/a | n/a | 8.4% |
| FY2022 | −24.0% | −24.0% | 15.8% |
| FY2021 | n/a | n/a | 5.1% |
| FY2020 | −34.9% | −35.9% | 26.6% |
| FY2019 | −46.0% | −46.4% | 24.8% |
| FY2018 | −26.3% | −26.6% | 31.5% |
| FY2017 | −15.7% | −16.5% | 34.9% |
| FY2016 | −29.2% | −16.1% | 29.7% |
| FY2015 | −6.7% | −13.5% | 31.1% |
| FY2014 | −4.2% | −8.7% | 32.6% |
| FY2013 | 8.3% | 7.9% | 37.5% |
| FY2012 | 9.0% | 8.3% | 37.8% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q1 FY27 | n/a | n/a | n/a | |
| Q4 FY26 | −84.8% | +8.8 pts | n/a | |
| Q3 FY26 | −96.5% | −11.1 pts | n/a | |
| Q2 FY26 | −90.3% | n/a | n/a | |
| Q1 FY26 | −74.8% | n/a | n/a | |
| Q4 FY25 | −93.6% | n/a | −96.7% | |
| Q3 FY25 | −85.4% | n/a | −89.8% | |
| Q2 FY25 | n/a | n/a | n/a | |
| Q1 FY25 | n/a | n/a | n/a | |
| Q4 FY24 | n/a | n/a | n/a | |
| Q3 FY24 | n/a | n/a | n/a | |
| Q2 FY24 | n/a | n/a | n/a |
Against its peers
Companies in Healthcare nearest Biomerica's size, closest first, today.
| Company | Profit margin |
|---|---|
| BMRABiomerica | n/m |
| NEPHNephros | 8.4% |
| ATNMActinium Pharmaceuticals | n/m |
| APTAlpha Pro Tech | 6.8% |
| SPROSpero Therapeutics | 15.7% |
| LFVNLifevantage | 2.8% |
| Peer median | 7.6% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Biomerica
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.